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Photochemotherapy offers a unqiue approach for the 
select ive ther a py of skin diseases. Hematoporphyrin de-
rivative (HPD) in combination with visible light exhibits 
cytocidal activity in vitro and systemically has demon-
strated applicability to the treatment of experimental 
and human tumors. This study was undertaken to inves-
tigate the phototoxic effects in guinea pig skin of sys-
temic HPD in comparison with locally (intradermal) and 
topically administered HPD. 
Maximum erythema was obtained by irradiation with 
red light or UVA 6 h postsystemic HPD (10 mg/kg). 
E r ythema response was dependent upon the dose of ir-
radiation. Systemic HPD produced complete inhibition 
of epidermal DNA, RNA, a nd protein synthesis 6-12 h 
postirradia tion with red light, with a lesser degree of 
inhibition in the deeper hair roots . Local (intradermal) 
HPD (5-500 IJ.g) in combination with red light or UV A 
produced a dose-dependent erythema and inhibition of 
epidermal DNA synthesis. Effective in vitro percuta-
neous penetration of HPD was demonstrated in vehicles 
containing Azone and N-methylpyrrolidone. Topical ap-
plication of these HPD formulations in vivo in combi-
nation with red light or UV A produced significant ery-
the ma and inhibition of epidermal DNA synthesis. These 
results suggest that HPD can cause photosensitization of 
the skin. It ma y therefore be r ea sonable to explore top-
ica l a pplicat ions as a n alternative a pproach for the pho-
toche mother apy of psoriasis and other cutaneous dis-
eases. 
P hotochemotherapy provides an ideal method to localize the 
effects of a drug to the skin by using a drug that is inactive in 
the body, but can cause photoactivation in t he skin. For ex-
ample, ora l methoxsalen and long-wave UV radiation (PUV A) 
is an effective t reatment for cutaneous di seases such as pso-
riasis, vit iligo, and mycosis fun goides. 
Hematoporphyrins, and in particular hematoporphyrin de-
rivative (HPD), have been studied in recent years for the 
diagnosis and t reatment of malignant di sease. HPD is selec-
t ively localized in animal a nd human malignant t issues [1 ,2 ) 
and has been used photodynamically to selectively destroy 
malignant t issue while leaving t he surrounding normal tissue 
relatively unda maged. Several clinical trials using HPD pho-
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toirradiation t herapy have been reported in patients with cu-
taneous or subcutaneous malignant t umors [3-5]. 
The present investigation was undertaken to develop a topi -
cal formulation of HPD with effective percutaneous penetra-
tion and to evaluate the photosensitizing effects of this topical 
formulation in guinea pig skin in vivo in comparison wit h 
systemica lly and locally (int radermal) administered HPD. 
MATERIALS AND METHODS 
Hematoporphyrin derivative (Oncology Research and Development, 
Inc., Cheektowaga, New York) was obtained as a 5 mg/ml saline 
solut ion (Photofrin) . T o prepare the topical formulations, this material 
was lyophylized in t he dark and reconstituted in t he selected vehicle. 
Vehicles were obtained commercia lly: Azone {1-dodecylazacyclohep-
tan-2-one), N- methylpyrrolidone (Nelson Research, Irvine, California ), 
Eucerin cream (Beiersdorf Inc., South Norwalk , Connecticut ), Vehicle 
N (Neut rogena Corporation, Los Angeles, California ), Aquaphor oint-
ment base (Duke Laboratories, South Norwalk , Connecticut), Unibase 
oin t ment base (Parke-Davis, Detroit, Michigan) , dimethylacetamide 
(Aldrich Chemical Corp. , Milwaukee, Wisconsin), and dimethylsulf-
ox ide (M allinckrodt Inc. , Paris, Kentucky). 
In Vitro Percutaneous Penetration Assay 
The percutaneous penetration of HPD was measured in glass diffu-
sion cells using the technique previously described [6]. Full -thickness 
skin excised from the backs of HRS/J albino hairless mice was used 
for t hese studies. HPD at a concentration of 1% in various vehicles 
was applied to the epidermal surface (0.2 ml /cm2) . A total of 2.5 mg of 
HPD was applied to eac h di ffu sion cell. The dermal reservoir conta ined 
phosphate-buffered saline. Three diffusion cells were run for each 
vehicle. Diffusion cells were incubated wit h consta nt stirring at 28"C. 
HPD penetration was qua nt itated by fluorometric ana lys is using a n 
Aminco-11uoro-colorimeter equipped with Corning 5-56 excitation and 
2-62 emission filters. Skin specimens were removed from t he diffusion 
chamber upon completion of t he study and frozen in liquid nitrogen. 
Cryostat sections of the full -thickness skin specimens were examined 
for HPD lluorescence wi t h a Nikon AFM flu orescence microscope (BV 
excitation and W rat ten 2B ba rrier fil te rs). 
In Vivo A nimal Stu.dies 
Mature, female a lbino guinea pigs (Charles River Company) were 
housed individually a nd had free access to food and water. They were 
kept under natura l light and dark condi t ions un t il administration of 
the HPD, at which t ime t hey were placed in the da rk. Neet, a commer-
cia l ha ir depilatory prepa ration (Whiteha ll Laboratories), was used as 
directed to depilate the backs of the guinea pigs 24 h prior to the 
administration of HPD. 
Light Sources 
Two different light sources were used for irradiation. A red light 
source was provided by a modified 500-W slide projector, fil te red to 
pass light of wavelengths longer t han 600 nm (Corning 2418 fil ter) . 
The emission spectrum of the red light source was measured using a 
calibrated Model 742 UV-Visible Spectroradiometer (Optronic Labo-
ratories, Inc., Orlando, Florida) coupled wi th a H ewlett Packa rd Model 
85 co mputer wi t h 1/ 0 ROM and BCD inte rface automatic data reduc-
tion system. The peak output of the light source was between 600- 700 
nm , delivering 9.8 m W /cm2 at a distance of 10 em from t he lens. The 
light source, placed 10 em above the exposure site, delivered doses (of 
8.8 J /cm2, 17.6 J /cm2, or 35.2 J /cm2) , representing exposure t imes of 
15, 30, a nd 60 min, respectively. The UVA radiation source was pro-
vided by a bank of 8 UV A lamps (pea k emission level 360- 365 nm) 
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contai ned in a HOUVA-Lite hand-foot unit (National Biological Cor-
poration, Cleveland, Ohio). The light intensity measured by a LM301 
light meter (National Biological) was approximately 9 mW /cm2 at a 
distance of 10 em from the treatment sites, delivering doses of 8.1, 16.2, 
or 32.4 J /cm2, represent ing exposure t imes of 15, 30, or 60 min, 
respectively. During light exposures animals were restrained a nd lightly 
anesthetized with xylazine and ketamine. 
HPD Administration 
Systemic HPD was administered i.p. at a dose of 10 mg/kg. HPD in 
quantities of 0.5- 500 11g was administered intradermally in a 0.1-cc 
isotonic sterile saline solution. Various topical HPD preparations or 
vehicle control solutions (0.1 ml) were applied to the back skin (1.5 
Xl.5 em area) one or more times before irradiation. Excess HPD was 
washed off t he skin by mild soap and water immediately prior to 
irradiation. This effectively removed all HPD from the skin surface, 
alt hough residual HPD in the skin was evident from t he reddish color 
that remained afte r washing. Fluorescence microscopy also revealed 
high levels of HPD concentrated in t he stratum corneum following the 
washing procedure. All treatments were done in duplicate in each 
animal. Both upper and lower back were used in these studies, with 
t reatment and cont rol sites localized to similar anatomic regions. 
Erythema Evaluation 
Photosensitization by HPD as manifested by delayed erythema was 
evaluated at various t ime intervals after irradiation using the following 
scale: 0- no reaction; 1 + - minimal erythema with sharp borders; 2+ -
more pronounced, bright , erythema without edema; 3+- marked ery-
thema with edema; 4+- violaceous erythema with vesiculation. 
A u.toradiographic Stu.dies 
Autoradiographic techniques were used to study the effects of sys-
temic HPD (10 mg/kg) and red light on epidermal macromolecular 
synt hesis in vivo. At various t imes after light exposure, animals were 
injected intradermally in to separate sites with 0.1 cc containing 10 11Ci 
of [methyl-3H] t hymidine (25 Ci/ mmol, Amersham), [5-'1H]uridine (30 
Ci/ mmol) , a nd L-(4,5-3H]leucine (30.7 Ci/mmol, New England Nu-
clear) at both areas exposed to light, as well as control areas which 
were not irradiated. One hour afte r isotope administration the injected 
sites were biopsied with a 4-mm punch, fixed in Bouin's fixative for 24 
h, and prepared histologically for autoradiography [7] . The slides were 
coated with Kodak NTB-2 liquid nuclear track emulsion for 6 weeks, 
developed, and stained with hematoxylin and eosin. The labeling index 
was determined as a measure of DNA synthesis by counting the number 
of labeled basal cells per 1000 in te rfollicular basal cells. Epidermal 
RNA (['lH]uridine) and protein {['lH]leucine) synt hesis was scored 
qualitatively on a scale of 0- 3+ , based on a composite of gra in content 
a nd number of labeled cells. A cell was considered labeled if it contained 
5 or more gra ins per cell. All sections were scored by 2 independent 
observers a nd the resul ts averaged. The auto radiographic results were 
expressed as percent of control: 
lab ling of HPD plus light-treated sites (x100) 
labeling of unirradiated sites 
Sim ila r autoradiographic techniques were used to study the effects of 
intradermal and topical HPD with irradiation on DNA synthesis. 
RESULTS 
Systemic HPD Administration 
Maximal erythema (2-3+, at 24 h after light) was produced 
by administering red light (35.2 J /cm~ ) 6 h after a single 
systemic dose of HPD (10 mg/kg) . One+ erythema was pro-
duced if light was administered at either 2 h or 12 h after the 
HPD t reatment . 
The effect of systemic HPD and irradiation with red light on 
DNA, RNA, and protein synthesis in t he ep idermis and hair 
root was studied using autoradiographic techniques (Fig 1). In 
the epiderm is there was complete inhibition of DNA, RNA, 
and protein synthesis wit hin 6- 12 h following irradiation , which 
was maintai ned for the 72-h observat ion period. In hair roots 
t here was complete inhibit ion of DNA synthesis for 6 h postir-
radiation, bu t a partial (approximately 50%) recovery occurred 
by 72 h. Compared to the epidermis, t here was a lesser degree 















0 2~ Time olt er Red Light (HR) 48 72 
FIG 1. Effect of systemic HPD and red light on macromolecula r 
synthesis. Animals were irradiated with red light (35.2 J / cm2 ) 6 h 
following systemic HPD (10 mg/kg i.p.) . Tritiated thymidine (DNA) , 
uridine (RNA) , and leucine (protein) were injected at separate sites at 
the various t ime in te rvals following irradiat ion. RNA (.A.), DNA (e ) , 
and protein synthesis (•) in epidermis (--) and hair roots ( · · · ·) 
analyzed autoradiographically, as described in Materials and Methods. 
Values represent t he mean of 4 animals. 
24 Time a lt or UVA (HR) 46 7 2 
FIG 2. Eryt hemogenic effect of systemic H PD and UVA. Animals 
received HPD (10 mg/ kg) i.p. 6 h before UVA (0: no UVA; •: 8.1, .A.: 
16.2, e: 32.4 J/cm2 ). 
also with a more rapid rate of recovery. This differential effect 
on t he epidermis vs. the hair root may reflect a relatively lower 
dose of irradiation reaching the hair roots because of their 
depth in the skin. 
Treatment with UVA (8.1 , 16.2, 32.4 J / cm2 ) 6 h after systemic 
HPD produced no immediate erythema, but reached 2+ ery-
thema at 24 h (Fig 2). The erythema response at 72 h was 
dependent upon the dose of UV A, with greater erythema seen 
with the higher dose of UV A (32.4 J / cm2 ) . These higher doses 
of UV A produced histologic changes of subepidermal vesicles 
and linear necrosis of basal cells consistent with a phototoxic 
response. No erythema was observed in nonirradiated skin. 
Intradermal (Local) HPD Administration 
HPD was administered in t radermally to selectively deliver 
the drug to t he skin and thereby eliminate systemic exposure. 
The erythemogenic effect of intradermal HPD and irradiat ion 
with either red light or UV A is illustrated in Fig 3. Doses of 5-
500 J.Lg injected 6 h before light t reatment produced significant 
erythema with eit her red light or UV A. In each case there was 
a dose-dependent response with maximal erythema of 4+, 
vesiculation, and hair loss obtained with 500 J.Lg per injection 
site . There appears to be a more rapid onset of erythema with 
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4+ REO LIGHT 
3+ 
1+ 
o~--~~--~~---0~----~--~~----~ Time after Irradiation (HA) 
FIG 3. Erythemoge nic effect of intradermal HPD and red light or 
UV A. Doses of HPD (e: 500, .&.: 50, •: 5, 0: 0.5 !'g) were administeed 
6 h prior to irradiation with red light (35 .2 J/cm2) or UVA (32.4 J/cm2) 
and erythema graded at va rious time intervals thereafter. Mean values 
from 2 treatment sites from 1 animal. 
225 
oL---------~~----~~~~----------~ 0 · 24 Time after UVA (HR) 48 72 
FIG 4. Effect of intradermal HPD and UV A on epidermal DNA 
synthesis. Doses of HPD (e: 500, .&.: 50, • : 5, 0: 0.5 !'g) were adminis-
tered 6 h prior to irradiation with UVA (32.4 J/cm2). Tritiated thymi-
dine was injected intradermally into the HPD-treated sites at various 
times after UV A and DNA synthesis were analyzed autoradiographi-
ca lly as described in Materials and Methods. Mean values of 4 biopsies 
from 2 different t rea tment sites as described in Fig 3. 
red light, which produces clinical effects at 24 h and maximal 
response at 48 h after irradiation. With UV A, on the other 
hand, erythema is not seen until 48 h after irradiat ion, with 
maximal response at 72 h. 
The intradermal administration of HPD and UV A irradia-
tion also produced an inhibit ion of epidermal DNA synthesis 
(Fig 4). Doses of 50 and 500 f..l.g HPD produced complete 
inhibition of DNA synthesis at 24 h with continued inhibition 
for the 72-h observation period. A less pronounced inhibitory 
effect was seen with the lower doses (0.5, 5 f..l.g) which was 
accompanied by a stimulation in DNA synthesis at 48- 72 h. 
Topical HPD Administration 
Having shown that local (intradermal) delivery of HPD 
produces an erythemogenic effect and inhibits epidermal DNA 
synthesis, experiments were undertaken to develop a topically 
effective preparation of HPD. The in vitro percutaneous pen-
etration of HPD was measured in various vehicles (Table I). 
The penetration of HPD was enhanced by all vehicles compared 
to saline. Increasing concentrations of Azone from 0.5 to 2% 
enhanced HPD penetration. Maximum HPD penetration was 
obtained with the Azone:isopropanol:H20 (2:50:48) vehicle (183 
f..l.g/cm 2)/48 h) . Fluorescence microscopy of skin sections treated 
with HPD in this vehicle show a more intense fluorescence in 
Vol. 81, No.6 
TABLE I. Topical HPD (1 %) percutaneous penetration in vitro and 
phototoxic activity in vivo 
Vehicle 
Saline 
Azone: isopropanol:H, O (2:50:48) 
Azone:ethan oi:H,O (2:93:5) 
Azone:ethanoi:H,O (1:94:5) 
Azonc:c thanoi:H,O (0.5:94.5:5) 
N- methylpyrrol idone:isopropanol: H,O 
(43:30:27) 
Dimethylsulfoxide:H,O (80:20) 







at 48 h" 
(!lg/cm' ) 
22 ± 3 
183 ± 32 
127 ±50 
96 ± 16 
48 ± 8 















"Penetration of 1% HPD through hairless mouse skin quantitated by fluoro -
metric assay. 
'' T opical 1% HPD applied 3 times prior to UVA irradiation (32.4 J /cm' ) or 
red light (35.2 J/cm') as desc ribed in Fig 7. 
' Experiment not done. 
FIG 5. Fluorescence microscopy photomicrograph of skin 48 h after 
topical treatment with 1% HPD in (A) saline and (B) Azone: isopro-
panol:H20 (2:50:48). Fluorescence indicates HPD distribution. 
the stratum corneum (Fig 5B), reflecting a higher concentra-
tion ofHPD in that site. In comparison to the stratum corneum, 
there is less red f1uorescence in t he epidermis and surrounding 
hair follicles (Fig 5B). The lack of HPD penetration in the 
saline vehicle is demonstrated in Fig 5A with deposition of 
HPD on t he superficia l layers of the stratum corneum, with 
negligible penetration into the epidermis or dermis. Histologic 
examination of vehicle controls were without evidence of dam-
age to the stratum corneum, except at the high concentrations 
ofDMSO. 
Various topical formulations of HPD were evaluated for their 
erythemogenic effect with UV A and red light irradiation. These 
results are summarized in Table I. Only the Azone-isopropanol-
H20 and t he N-methylpyrrolidone (NMP) vehicles with HPD 
provided significant erythema. Both HPD formulations pro-
duced a 2-3+ erythema at 48 h following irradiation with either 
red light or UV A. Histologic changes produced by these topical 
HPD formulations 48-72 h postirradiation included marked 
superficial crusting, epidermal necrosis, subepidermal bullae, 
and a dermal inflammatory infiltrate (Fig 6B). In contrast, the 
vehicle plus light (Fig 6A) or HPD without light (not shown) 
showed no evidence of erythema and remained histologically 
normal. Topical HPD in either the Azone or NMP vehicle 
produced complete inhibition of epidermal DNA synthesis 
(control labeling index = 16.1%) with a lesser degree of inhi -
bition in the deeper hair roots (Fig 6B) as compared to the 
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FIG 6. Autoradiographs of guinea pig epidermis treated (x3) wit h (A) vehicle: (Azone:isopropa nol:H20 (2:50:48)) or (8 ) 1% HPD in vehicle; 
t issues labeled with t rit iated thymidine 48 h a fter UVA irradiation (32.4 J jcm2 ) . Arrows indicating [' H] thymidine- labeled cells. Epidermal 










Time after irradiation (HR) 
FIG 7. Erythemogenic effec t of topical HPD (1 %) (e) and 5% (A) 
in N-met hylpyrrolidone:isopropa nol :H20 (43:30:27). Vehicle cont rol: (•) . Animals received 3 topical applications of test solut ions at 28, 16, 
and 4 h prior to UVA irradiation (32.4 J /cm2) . Va lues represent the 
mean determination of 2 t reatment sites for 2 di fferent animals. 
vehicle-treated control (Fig 6A) or HPD-unirradiated sites. 
Slight erythema (1 - 2+) was seen with HPD in the Eucerin 
cream base. 
The effect of HPD concent ration in the NMP vehicle on 
erythema production is summarized in Fig 7. There was a slight 
increase in the duration of erythema at 48 h with the 5% vs. 
the 1% HPD. However, by fluorescence microscopy it appears 
that maximum HPD skin content is achieved with the 1% 
HPD/ NMP formulation as compared to 5% HPD in NMP 
afte r 3 applications. Three applications of HPD within a 24-h 
period produced a greater degree of erythema with both the 1% 
and 5% formulations, than did a single application adminis-
tered 4 h prior to UV A (data not shown) . 
DISCUSSION 
Photochemotherapy can be used to achieve localized effects 
of a drug in t he skin , as for example with P UV A t herapy of 
psoriasis. The present study has shown phototoxic effects in 
gu inea pig skin of systemic HPD, int radermal and topically 
administered HPD. Although the mechanism of action of the 
cytotoxicity of HPD is not clear, it is t hought to involve damage 
of t he plasma membrane [8] by singlet oxygen [9]. However, 
there is evidence that HPD upon photoactivation by appropri -
ate wavelengths can resul t in single-strand breaks in DNA in 
bacteria [10] and also in human cells in vit ro [11] . As with 
PUV A, this factor may be a concern in the use of HPD for 
therapeut ic purposes. 
Photoactivation of HPD has been used in the experimental 
t reatmen t of human cancer. Recent studies have suggested t hat 
systemic HPD in combination with UV A irradiation is effective 
in t he therapy of pso riasis [12]. In t his preliminary cl inical 
study, a single systemic dose of HPD (1mg/kg) in combination 
with repeated exposures to UV A effectively cleared psoriasis in 
15 of 20 patients. The dose of HPD used in psoriasis was much 
lower than the standard dose of 5-10 mg/kg used in the t reat-
ment of cance r. The single dose of H PD used to achieve 
photosensit ization by subsequent t reatments with UV A sug-
gests possible retention of HPD in psoriatic epidermis. T he 
well-known prolonged photosensitivity caused by systemic 
HPD [13] is a lso consistent wi th t he prolonged retent ion of 
HPD in normal skin . The localized t reatment of psoriasis by 
topical delivery of HPD would serve to minimize phototoxicity 
of normal skin. 
The action spectrum of H PD, the opt imum wavelengths to 
achieve phototoxicity, has not been established. The absorption 
spectrum of HPD conta ins several peaks in the visible range, 
wi th max imum absorpt ion in the UVA range [14]. P hototox-
icity can be seen with UV A as well as various parts of the 
visible light spectrum depending on the light energy. Red light 
in the range of 620-640 nm (corresponding to a minor HPD 
absorpt ion band) is used in the t reatment of tumors because of 
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deeper tissue penetration of the longer wavelengths. On the 
proposed basis of t reating diseases in the superficial part of t he 
skin, the epidermis, photoactivation with UV A was selected for 
the present studies. In the present investigation we have dem-
onstrated cutaneous phototoxicity with red light as well as 
UV A by systemic and local (intradermal and topical) adminis-
tration of HPD. Topical HPD and UVA irradiation produced 
a more potent inhibit ion of DNA synthesis in t he epidermis vs. 
the deeper hair roots. This may be due to a less effective 
penetration of HPD and/or a lesser amount of light reaching 
the deeper tissue. This selectivity would be a desirable factor 
in the topical therapy of skin diseases. The intradermal studies 
which demonstrated an HPD dose-dependent erythema and 
· inh ibition of DNA synthesis, suggest that a minimum HPD 
local tissue level of 5 JJ.g/gm tissue is required to produce these 
effects. In vitro percutaneous penetration experiments have 
demonstrated several veh icles t hat should provide adequate 
tissue levels. The lack of correlation of the in vit ro HPD 
percutaneous penetration with topical phototoxic activity may 
be due to a number of factors such as selective retention of 
HPD in the epidermis/dermis by various vehicles, which is not 
detected by total penetration. In addition, since HPD repre-
sents a mixture of components, the photoactive component 
may be different from t hat measured fluorometrically in these 
assays. 
T he topica l use of HPD is also a consideration for the 
phototherapy of other skin diseases such as actinic keratoses, 
warts, and mycosis fungoides. Other potential clinical applica-
tions of topically applied HPD include premalignant and ma-
lignant gynecologic disorders susceptible to local t reatment. 
Recent experimental studies have shown a selective concentra-
tion or retention of topically applied HPD in chemically in -
duced dysplastic mouse epidermis vs. normal epidermis (M. A. 
Rettenmaier and J. L. McCullough, unpublished observations). 
The success of systemic HPD and light in t reating cutaneous 
tumors [15), such as basal cell carcinoma, squamous cell car-
cinoma, malignant melanoma, and mycosis fungoides, suggests 
that local (intralesional or topical) HPD phototherapy may be 
useful for the treatment of t hese tumors. Further studies need 
to be directed to the most effective veh icle delivery system, 
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drug scheduling, and source of irradiation for each of t hese 
clinical condit ions. Future studies on the identification of t he 
"active" component of HPD may lead to more effective vehicle 
delivery systems and enhanced therapeut ic effectiveness for the 
treatment of skin diseases. 
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